NCIC Clinical Trials Group
Abstracts to be Presented at the 35th Annual San Antonio Breast Cancer
Symposium
Henry B. Gonzalez Convention Center, San Antonio, Texas
December 4-8, 2012
WEDNESDAY, December 5th
Poster Session 1 – Exhibit Halls A-B - 5:00 pm to 7:00 pm
Prognostic and Predictive Factors: Biomarkers – Methods
MA.14 – J-A W Chapman
(P1-07-13)
Prognostic relevance of statistically standardized estrogen receptor (ER), progesterone receptor
(PR), and human epidermal growth factor receptor 2 (HER2) in tamoxifen(TAM)-treated NCIC
CTG MA.14 patients
Treatment: Chemotherapy – Adjuvant
MA.21 – MJ Burnell
(P1-13-01)
A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by
paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG
MA.21: Results of the final relapse free survival analysis
THURSDAY, December 6th
Poster Session 2 – Exhibit Halls A-B - 7:00 am to 9:00 am
Treatment: Endocrine Therapy – Adjuvant
MA.27 – MJ Higgins
(P2-13-02)
Effect of aspirin (ASP) or celecoxib (CC) use on outcomes in postmenopausal breast cancer
patients randomized to adjuvant exemestane or anastrozole: NCIC CTG MA.27